Antibody-Mediated Autonomic Neuropathy

$248,388P50FY2009NSNIH

Mayo Clinic Rochester, Rochester MN

Investigators

Linked publications & trials

Paper 28236005 Paper 26586909 Paper 26141615 Paper 26114921 Paper 25870188 Paper 25557731 Paper 25448247 Paper 25260537 Paper 25211238 Paper 25041866 Paper 25033770 Paper 24909319 Paper 24414173 Paper 23218087 Paper 22993288 Paper 22795533 Paper 22421352 Paper 22357716 Paper 22228725 Paper 22127477 Paper 21996154 Paper 21807569 Paper 21802629 Paper 21684854 Paper 21135384 Paper 21098403 Paper 20942898 Paper 20733151 Paper 20732833 Paper 20700642 Paper 20547476 Paper 20439562 Paper 20221842 Paper 20167544 Paper 20142529 Paper 20044994 Paper 19884578 Paper 19768767 Paper 19729859 Paper 19720940 Paper 19683968 Paper 19597132 Paper 19541551 Paper 19520617 Paper 19506222 Paper 19506134 Paper 19345959 Paper 19280245 Paper 19207771 Paper 19058765 Paper 18990321 Paper 18951069 Paper 18791476 Paper 18756006 Paper 18704621 Paper 18567861 Paper 18498681 Paper 18485491 Paper 18474849 Paper 18420158 Paper 18368301 Paper 18326553 Paper 18297292 Paper 18174390 Paper 18064475 Paper 17717719 Paper 17687267 Paper 17673566 Paper 17654557 Paper 17639427 Paper 17626834 Paper 17536048 Paper 17502489 Paper 17353381 Paper 17352367 Paper 17337590 Paper 17275763 Paper 17235127 Paper 17160588 Paper 17143044 Paper 17110507 Paper 17089135 Paper 16718689 Paper 16670175 Paper 16648188 Paper 16513672 Paper 16476936 Paper 16476804 Paper 16301478 Paper 16293706 Paper 16221272 Paper 16212146 Paper 16191112 Paper 16032381 Paper 15993134 Paper 15946964 Paper 15946904 Paper 15863453 Paper 15802370 Paper 15782421

Abstract

Project 4 will focus on defining autoimmune autonomic neuropathy (AAN) as an antibody-mediated disorder and will evaluate features of antibody-mediated autonomic failure that may be relevant to other dysautonomic syndromes. Studies in this project will provide a direct translational component to the clinical studies of AAN in Project 1 (Dr. Phillip Low) and physiological and serological correlates to the clinical studies of orthostatic tachycardia syndrome (POTS) in Projects 1 and 3 (Dr. Michael Joyner).

View original record on NIH RePORTER →